CD56 antigen, a 200-220 kDa cell surface glycoprotein, identified as an isoform of the neural adhesion molecules (NCAM), has been found frequently expressed in several lympho-hematopoietic neoplasms including acute myeloid leukemias (AML). In fact, in these latter diseases it has been reported that the presence of CD56 antigen on the blasts of AML patients with t(8;21) (q22;q22), and in those with M3 subtype, identifies a subgroup of patients with a more unfavorable prognosis. On the basis of these findings, we evaluated in 152 newly diagnosed AML patients CD56 surface expression, and results were correlated with morphology, immunophenotype, cytogenetic pattern and clinical outcome. CD56 antigen was recorded in 37 out of 152 cases (24%) and particularly in those with M2 and M5 cytotypes. Moreover, CD56 expression was significantly associated with P-glycoprotein (PGP) hyperexpression (P = 0.007), unfavorable cytogenetic abnormalities (P = 0.008) and with a reduced probability of achieving complete remission (CR) (36% vs 68%) (P = 0.035) as well as with a shorter survival (6 vs 12 months) (P = 0.032). In conclusion, CD56 antigenic expression on AML cells represents an important adverse prognostic factor and therefore its presence should be regularly investigated for a better prognostic assessment of AML patients at diagnosis. Leukemia (2001) 15, 1161-1164.
Introduction
Acute myeloid leukemias (AML) could be considered as a heterogeneous group of disorders which often present with different morphological, immunophenotypic and cytogenetic patterns. [1] [2] [3] [4] [5] Identification of these characteristics may be useful for a better prognostic evaluation and for a more appropriate therapeutic approach.
Different immunophenotypic studies carried out on AML patients demonstrated that several antigens expressed on AML cells, such as CD7, CD34, bcl-2, represent important independent prognostic factors that affect the clinical outcome of these patients. [6] [7] [8] [9] [10] [11] More recently, CD56 antigen, a 200-220 kDa cell surface glycoprotein, identified as an isoform of the neural adhesion molecules (NCAM) [12] [13] [14] was firstly described as a marker of natural killer cells and subsequently, has also been found expressed in several lympho-hematopoietic neoplasms including acute myeloid leukemias (AML). [15] [16] [17] [18] [19] [20] [21] [22] In fact, it has been previously reported that in AML patients with t(8;21) (q22;q22), generally considered at lower risk of relapse, the presence of CD56 antigen on blast cells may influence complete remission (CR) duration and survival, 23 suggesting that CD56 expression could be useful in stratifying therapeutic approaches for this subtype of AML. 23, 24 Similar data have also been reported in patients with acute promyelocytic leukemias (APL) where the presence of CD56 antigen on APL blasts seems to identify a poorer risk prognostic group. In order to better clarify the prognostic role of CD56 expression in AML cells, in the present study we evaluated the presence of this antigen on leukemic cells of 152 newly diagnosed AML patients, and results were correlated with the presence of other antigens with prognostic significance, cytogenetic pattern and clinical outcome.
Patients and methods
One hundred and fifty-two, consecutive, de novo AML adult patients diagnosed according to FAB critera 2 entered the study. All patients under 70 years underwent the same chemotherapy protocol consisting of first-line induction and consolidation regimens. First-line induction regimen comprised a 7-day continuous infusion of standard-dose cytosine arabinoside (200 mg/m 2 ) and daunorubicin (45 mg/m 2 , in 1 h) for 3 days (3-7 protocol). M3 patients were excluded from the analysis, since they received different treatment. The consolidation treatment included the administration of high-dose cytosine arabinoside (500 mg/m 2 , twice daily, days 1-6) and mitoxantrone (12 mg/m 2 , days 4-6). Patients Ͼ65 years old had reduced drug doses and 33 out of 120 evaluable patients underwent autologous or allogeneic bone marrrow transplantation within 6 months after achieving CR.
Before starting chemotherapy, adequate immunophenotypic studies and, in the majority of patients, karyotypic analyses were performed.
Immunophenotypic analysis
Immunophenotypic characterization of leukemic cells was assessed on fresh and/or cryopreserved mononuclear cells obtained following Lymphoprep gradient from bone marrow and/or peripheral blood using a direct immunofluorescence technique by flow cytometry (FACScalibur; Becton Dickinson, San Jose, CA, USA) as previously described. 26 In particular, the following panel of monoclonal antibodies (MoAbs) was used: CD13, CD14, CD33, CD34, CD2, CD4, CD19, CD41, CD117, glycophorin A and appropriate isotype controls (Becton Dickinson and Dako, Glostrup, Denmark). For detection of CD56 antigen on leukemic cells an anti-CD56 phycoerythrin (PE)-conjugated MoAb was used (Leu 19, NCAM 16.2, Becton Dickinson) in multiparameter flow cytometry by gating leukemic cells on forward and side light scatter parameters and using two-color staining with CD56 and CD13 or CD33 or CD34 MoAbs in order to exclude CD56 expression on lymphocytes. Antigen was considered positive when at least 15% or more of the cells were stained.
Bcl-2 protein expression was analyzed by direct immunofluorescence tecnique using anti-bcl-2 124 FITC MoAb (Dako), 11 while P-glycoprotein (PGP) expression was tested in leukemic cells using MRK-16 antibody (Kamiya) by an indirect Leukemia immunofluorescence technique. 27 In both cases single-color analysis was employed and appropriate isotype controls were assessed. Bcl-2 and PGP expression was defined considering both the percentage of positive cells and the mean fluorescence index (MFI) expressed as the ratio of sample mean channel:control mean channel. In all cases 10 000 events were acquired and analyses were performed by the CellQuest software in a FACScan instrument (Becton Dickinson).
Cytogenetic analysis
The chromosome analysis was performed at diagnosis on short-term cultures from bone marrow blast cells using Gbanding with Wright's stain and in each case at least 20 mitosis were analyzed and karyotype aberrations were described according to ICSN guidelines. 28 Abnormalities were defined as favorable if t(8;21), inv(16) or t(16;16) were found; unfavorable in the case of 7/7q−, 5/5q−, del(11)(q23), del(3), t(9;22) or in the case of more than three chromosomal anomalies (complex karyotypes). All other karyotypic abnormalities or normal diploid karyotypes were defined as intermediate. 29 
Statistics
Since the main aim of this study was to evaluate CD56 expression on AML blast cells and to correlate these findings with the clinical outcome, the response rate was evaluated after induction therapy only in patients receiving an adequate treatment. Yates corrected chi square test was emploiyed to compare the differences between groups. Correlation among CD56 expression and other membrane antigens was estimated using Spearmen's correlation coefficient. Multivariate and univariate logistic regression tests were employed to identify the variables affecting the clinical outcome. All the parameters of significant value in univariate analysis were entered in multivariate analysis. Then a backward procedure was adopted to remove the least significant factors until only variables with significant value were retrievable. Survival was calculated according to Kaplan and Meier. 30 In the analysis of CR duration, transplanted patients were censored at the time of transplantation. The log rank test for heterogeneity 31 and Cox's proportional hazard model 32 were applied to discriminate factors affecting survival. Early death or failure to enter remission were considered an event at zero time.
Results
One hundred and fifty-two de novo AML patients at diagnosis entered the study: 80 were males and 72 were females with a median age of 50 years (range 14-82). According to FAB criteria, 10 patients were classified as M0, 33 as M1, 27 as M2, 43 as M4, 37 as M5 and two as M7.
Correlation of CD56 expression with immunophenotype and karyotype
Samples from all patients were studied with a large panel of MoAbs and immunophenotypic analysis showed that almost all AML patients expressed CD13 and CD33 on leukemic cells, while CD56 antigen was detected in only 37/152 cases (24%) with a percentage of positive leukemic cells ranging from 15 to 97% (median 42%).
CD56 antigen was rarely expressed in M0 patients, but was more frequently expressed in M2 and M5 cases. In the majority of cases, CD56 expression on leukemic cells was bright as in normal NK cells, independently by the FAB subtype or cytogenetic abnormalities. Furthermore, CD56 expression was correlated with the expression of other antigens generally associated with unfavorable outcome such as CD34, CD7, bcl-2 and PGP. As shown in Table 1 , we were unable to find any significant correlation between CD56 and CD34 or CD7 and bcl-2 expression, however, despite the low number of cases (the last 76 patients considered in the study), an increased expression of PGP (MFI Ͼ6) was recorded in 14/18 (78%) CD56
+ patients and only in 22/58 (38%) CD56 − cases. Despite the small number of cases, these results suggest a strict correlation between CD56 positivity and PGP overexpression (P = 0.007). Cytogenetic analysis was evaluable only in 132 out of 152 patients, 35 of whom were CD56 + and 97 CD56 − , since in 12 patients the studies were not performed and in the remaining eight we were unable to obtain mitosis. In both groups, clonal abnormalities, characteristically associated with AML, such as t(8;21), inv(16), t(16;16), 7/7q−, 5/5q−, del(11)(q23), del(3), t(9;22) and complex karyotypes were recorded. Notably, the incidence of patients with t(8;21) (q22;q22), was negligible in our series since only 3/35 CD56 + and 1/97 CD56 − AML cases presented with this cytogenetic abnormality. Nevertheless, a significant correlation between CD56 expression and cytogenetic abnormalities associated with unfavorable prognosis was documented both in univariate and multivariate analysis (P = 0.008 and 0.025, respectively) ( Table 1) .
Correlation of CD56 with remission rate and outcome
To address the hypothesis of whether CD56 expression could represent an adverse prognostic factor in AML, its presence was correlated with clinical response. The response was evaluated after induction therapy in 120/152 patients who received the same treatment. Six AML patients, equally distributed in both the CD56 + and CD56 − patients, who died during induction (DDI) (ie death during the first period after induction therapy before hematological recovery) were considered as failure in the response analysis and regularly included in the survival analysis. The overall CR rate in our series of patients was 59%. However, among CD56 − patients, CR was achieved in 59/87 patients (68%),but only in 12 out of 33 (36%) evaluable CD56
+ cases (P = 0.035) ( Table 1 ). In addition, no other conventional prognostic factors such as age, WBC, CD34 or CD7 positivity influenced the response to therapy. In multivariate analysis only CD56 expression and cytogenetic abnormalities associated with unfavorable prognosis retained statistical significance, but CD56 represents an independent prognostic factor for the achievement of CR in AML (Table 2) . Overall, CD56 positivity did not influence CR duration. One explanation could be that a considerable number of patients (33/120) underwent bone marrow transplantation and therefore their CR duration was censored at the time of transplant.
Finally, survival analysis was performed and, as depicted in Figure 1 , in CD56
+ patients the median overall survival was shorter than in CD56 − cases (6 vs 12 months, respectively). However, it should be noted that this finding had a statistical significance (P = 0.032) together with other prognostic factors such as age (P = 0.0002), CD34 intensity of expression (P = 0.035), cytogenetic abnormalities (P = 0.001) and CD56 expression (P = 0.028). In contrast, in multivariate analysis, probably because of the low number of cases, overall survival was significantly affected only by age, WBC count, CD34 expression and not by CD56 expression.
Discussion
This study demonstrates that AML patients whose blasts express CD56 antigen, together with a reduced probability of achieving CR, have a shorter survival with respect to CD56 − patients.
Several studies have reported on the correlation between
Figure 1
Overall survival curves of AML patients according to CD56 expression.
Leukemia myeloid blast cell immunophenotype, morphology, cytogenetic pattern and patient's clinical outcome. [3] [4] [5] For example, lymphoid-associated antigens such as CD19, CD7 have been considered adverse prognostic factors for AML patients, [6] [7] [8] as well as the increased expression of CD34 and bcl-2 protein. [9] [10] [11] More recently, several studies have addressed the role of CD56 expression in hematological malignancies. In fact, this antigen, an isoform of the neural adhesion molecules (NCAM), has been recorded not only in aggressive non-Hodgkin's T cell lymphomas, 15, 16 but also in malignant plasma cells 33 and in several myeloproliferative disorders including acute leukemias. [18] [19] [20] [21] [22] [23] [24] [25] In this latter setting, CD56 expression was frequently associated with a poorer outcome, 23 as documented in AML patients with t(8;21) (q22;q22) and in APL cases, in which, the presence of CD56 antigen on the membrane of leukemic blasts led to a significant reduction of CR and overall survival duration. [23] [24] [25] In this study, conducted in a large series of AML patients, the presence of CD56 antigen was documented in 37/152 (24%), 33 of whom were also evaluable for response. Among these 33 CD56
+ patients, CR was documented only in 12 of them with a CR rate of 36%, significantly lower (P = 0.035) with respect to that observed in CD56
− patients where 59/87 (68%) achieved CR. Moreover, the adverse prognostic implication of CD56 expression on myeloid blast cells was also confirmed by the fact that in univariate statistical analysis the median duration of overall survival was significantly shorter (P = 0.028) in CD56 + than in CD56 − patients (6 months vs 12, respectively) ( Figure 1 ).
When correlated with FAB cytotype, CD56 expression, was more frequently detected in M2 and, particularly, in M5 AML patients. In these latter patients the finding could be attributed to the fact that the CD56 antigen is constitutively expressed in normal monocyte and monocyte-derived cells and monoblastic leukemias are generally associated with a poorer prognosis. The expression of CD56 was also correlated with lymphoid-associated antigens or antigens frequently associated with a negative prognostic significance such as CD7, CD34 and bcl-2 protein and no difference was found between CD56 + and CD56 − groups (Table 1) . In contrast, a more strict correlation was observed with the presence of multi-drug resistance (MDR)-related proteins. Since an increased expression and function of the PGP has been observed in normal CD56 + NK cells, 34, 35 we hypothesize that CD56 + AML blasts might overexpress PGP, a MDR-related protein, which may potentially increase the drug resistance mechanism and this may account for the reduced responsiveness to chemotherapy of CD56 + AML patients. This possibility is further strengthened by the observation, that in our series of patients, PGP expression was documented in 78% of CD56 + patients and only in 38% of CD56 − cases (P = 0.007). The last point which needs to be considered is the correlation between CD56 positivity and cytogenetic abnormalities. Unlike previous authors, 36 we were unable to find any correlation between CD56 expression and t(8;21) (data not shown), on the contrary, a significant correlation was found with cytogenetic abnormalities associated with unfavorable prognosis (P = 0.008) ( Table 1) . Nevertheless, univariate and multivariate statistical analysis demonstrated that the antigenic expression of CD56 represents an independent prognostic factor for the achievement of CR (Table 2 ).
In conclusion, our data suggest that CD56 antigenic expression in AML patients is more frequently associated with M5 FAB subtype, MDR overexpression and unfavorable cytogenetic abnormalities. Moreover, it correlates with a reduced probability of achieving CR and with a shorter survival, and therefore, the presence of CD56 antigen on myeloid blasts should be regularly assessed in AML patients at diagnosis, and should be taken into consideration in designing future therapeutic strategies based on patient-specific risk factors.
